(SFD) Smithfield Foods, Common - Overview
Stock: Packaged Meats, Fresh Pork, Hog Production, Heparin
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.49% |
| Yield on Cost 5y | 5.30% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | 58.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 19.0% |
| Relative Tail Risk | -8.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.76 |
| Alpha | 12.19 |
| Character TTM | |
|---|---|
| Beta | 0.422 |
| Beta Downside | 0.524 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.43% |
| CAGR/Max DD | 1.57 |
Description: SFD Smithfield Foods, Common January 07, 2026
Smithfield Foods, Inc. (NASDAQ:SFD) is a vertically integrated meat producer that operates three core segments: Packaged Meats, Fresh Pork, and Hog Production. The Packaged Meats segment turns fresh meat into branded and private-label products such as bacon, sausage, hot dogs, and ready-to-eat meals sold to retail and food-service customers. The Fresh Pork segment processes live hogs into primal and sub-primal cuts for domestic, export (e.g., China, Mexico, Japan) and industrial buyers. Hog Production raises hogs on company-owned and contract farms in the U.S. and Mexico and also sells grain to external customers. A bioscience unit extracts heparin from hog by-products for pharmaceutical use. Founded in 1936 and headquartered in Smithfield, Virginia, Smithfield is a subsidiary of SFDS UK Holdings Limited.
Key industry drivers for SFD include: (1) hog feed-cost volatility, which typically accounts for ~55% of total production expense; (2) pork price cycles tied to U.S. hog inventory levels-SFD’s 2023 hog inventory was roughly 12 million head, a 5% decline YoY, supporting higher pork prices; and (3) growing demand for protein in emerging export markets, where pork consumption in China has risen ~3% annually over the past five years. Recent financials show FY2023 revenue of $16.3 billion with an adjusted EBITDA margin of ~11%, reflecting the company’s scale and brand premium.
For a deeper dive into SFD’s valuation metrics and peer comparison, check out the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 864.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -4.55 > 1.0 |
| NWC/Revenue: 20.41% < 20% (prev 15.59%; Δ 4.82% < -1%) |
| CFO/TA 0.07 > 3% & CFO 803.0m > Net Income 864.0m |
| Net Debt (1.62b) to EBITDA (1.58b): 1.03 < 3 |
| Current Ratio: 3.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (394.6m) vs 12m ago 0.38% < -2% |
| Gross Margin: 13.24% > 18% (prev 0.12%; Δ 1312 % > 0.5%) |
| Asset Turnover: 137.6% > 50% (prev 133.2%; Δ 4.39% > 0%) |
| Interest Coverage Ratio: 26.47 > 6 (EBITDA TTM 1.58b / Interest Expense TTM 47.0m) |
Altman Z'' 4.22
| A: 0.27 (Total Current Assets 4.59b - Total Current Liabilities 1.48b) / Total Assets 11.52b |
| B: 0.31 (Retained Earnings 3.55b / Total Assets 11.52b) |
| C: 0.11 (EBIT TTM 1.24b / Avg Total Assets 11.09b) |
| D: 0.65 (Book Value of Equity 3.13b / Total Liabilities 4.80b) |
| Altman-Z'' Score: 4.22 = AA |
Beneish M -2.47
| DSRI: 1.79 (Receivables 1.04b/540.0m, Revenue 15.26b/14.19b) |
| GMI: 0.88 (GM 13.24% / 11.62%) |
| AQI: 0.93 (AQ_t 0.29 / AQ_t-1 0.31) |
| SGI: 1.08 (Revenue 15.26b / 14.19b) |
| TATA: 0.01 (NI 864.0m - CFO 803.0m) / TA 11.52b) |
| Beneish M-Score: -2.47 (Cap -4..+1) = BBB |
What is the price of SFD shares?
Over the past week, the price has changed by +2.38%, over one month by +12.66%, over three months by +13.08% and over the past year by +23.68%.
Is SFD a buy, sell or hold?
- StrongBuy: 4
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SFD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.4 | 20% |
| Analysts Target Price | 29.4 | 20% |
| ValueRay Target Price | 26.6 | 8.6% |
SFD Fundamental Data Overview February 05, 2026
P/E Forward = 10.4384
P/S = 0.621
P/B = 1.4652
Revenue TTM = 15.26b USD
EBIT TTM = 1.24b USD
EBITDA TTM = 1.58b USD
Long Term Debt = 2.00b USD (from longTermDebt, last quarter)
Short Term Debt = 72.0m USD (from shortTermDebt, last quarter)
Debt = 2.39b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.62b USD (from netDebt column, last quarter)
Enterprise Value = 11.09b USD (9.47b + Debt 2.39b - CCE 773.0m)
Interest Coverage Ratio = 26.47 (Ebit TTM 1.24b / Interest Expense TTM 47.0m)
EV/FCF = 23.50x (Enterprise Value 11.09b / FCF TTM 472.0m)
FCF Yield = 4.26% (FCF TTM 472.0m / Enterprise Value 11.09b)
FCF Margin = 3.09% (FCF TTM 472.0m / Revenue TTM 15.26b)
Net Margin = 5.66% (Net Income TTM 864.0m / Revenue TTM 15.26b)
Gross Margin = 13.24% ((Revenue TTM 15.26b - Cost of Revenue TTM 13.24b) / Revenue TTM)
Gross Margin QoQ = 12.78% (prev 13.15%)
Tobins Q-Ratio = 0.96 (Enterprise Value 11.09b / Total Assets 11.52b)
Interest Expense / Debt = 0.46% (Interest Expense 11.0m / Debt 2.39b)
Taxrate = 21.98% (71.0m / 323.0m)
NOPAT = 970.6m (EBIT 1.24b * (1 - 21.98%))
Current Ratio = 3.10 (Total Current Assets 4.59b / Total Current Liabilities 1.48b)
Debt / Equity = 0.37 (Debt 2.39b / totalStockholderEquity, last quarter 6.47b)
Debt / EBITDA = 1.03 (Net Debt 1.62b / EBITDA 1.58b)
Debt / FCF = 3.43 (Net Debt 1.62b / FCF TTM 472.0m)
Total Stockholder Equity = 6.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.79% (Net Income 864.0m / Total Assets 11.52b)
RoE = 13.92% (Net Income TTM 864.0m / Total Stockholder Equity 6.21b)
RoCE = 15.16% (EBIT 1.24b / Capital Employed (Equity 6.21b + L.T.Debt 2.00b))
RoIC = 11.82% (NOPAT 970.6m / Invested Capital 8.21b)
WACC = 6.04% (E(9.47b)/V(11.87b) * Re(7.47%) + D(2.39b)/V(11.87b) * Rd(0.46%) * (1-Tc(0.22)))
Discount Rate = 7.47% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 81.65 | Cagr: 0.19%
[DCF Debug] Terminal Value 87.94% ; FCFF base≈651.6m ; Y1≈803.8m ; Y5≈1.37b
Fair Price DCF = 92.77 (EV 38.09b - Net Debt 1.62b = Equity 36.47b / Shares 393.1m; r=6.04% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 78.15 | EPS CAGR: 15.67% | SUE: N/A | # QB: 0
Revenue Correlation: 20.81 | Revenue CAGR: -3.64% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.58 | Chg30d=-0.022 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=2.38 | Chg30d=-0.005 | Revisions Net=+1 | Growth EPS=-0.2% | Growth Revenue=+0.4%